Abstract
Etanercept is approved for the treatment of patients with moderate-to-severe active rheumatoid arthritis (RA), polyarticular juvenile RA, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. Randomized clinical trials have shown that it improves the signs and symptoms of early and long-standing RA and other inflammatory arthritides, prevents radiographic progression and improves the patients health-related quality of life. It is more effective when combined with methotrexate than alone. It is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by clinical trials, long-term observational studies and postmarketing surveillance over 12 years use in clinical practice. It slightly increases the risk of serious infections. The incidence of malignancies during clinical trials and postmarketing surveillance is no different from that expected in the general population, except for the greater frequency of lymphoma. However, this is closely related to current RA activity and therefore suggests that it is not directly related to the drug. This article considers the published data in terms of clinical practice and changes in the progression of RA.
| Original language | English |
|---|---|
| Pages (from-to) | 213-222 |
| Number of pages | 10 |
| Journal | Expert Review of Clinical Immunology |
| Volume | 8 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2012 |
Fingerprint
Keywords
- adverse events
- clinical efficacy
- etanercept
- pharmacokinetics
- safety
- trials
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Twelve years experience with etanercept in the treatment of rheumatoid arthritis : How it has changed clinical practice. / Atzeni, Fabiola; Sarzi-Puttini, Piercarlo.
In: Expert Review of Clinical Immunology, Vol. 8, No. 3, 03.2012, p. 213-222.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Twelve years experience with etanercept in the treatment of rheumatoid arthritis
T2 - How it has changed clinical practice
AU - Atzeni, Fabiola
AU - Sarzi-Puttini, Piercarlo
PY - 2012/3
Y1 - 2012/3
N2 - Etanercept is approved for the treatment of patients with moderate-to-severe active rheumatoid arthritis (RA), polyarticular juvenile RA, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. Randomized clinical trials have shown that it improves the signs and symptoms of early and long-standing RA and other inflammatory arthritides, prevents radiographic progression and improves the patients health-related quality of life. It is more effective when combined with methotrexate than alone. It is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by clinical trials, long-term observational studies and postmarketing surveillance over 12 years use in clinical practice. It slightly increases the risk of serious infections. The incidence of malignancies during clinical trials and postmarketing surveillance is no different from that expected in the general population, except for the greater frequency of lymphoma. However, this is closely related to current RA activity and therefore suggests that it is not directly related to the drug. This article considers the published data in terms of clinical practice and changes in the progression of RA.
AB - Etanercept is approved for the treatment of patients with moderate-to-severe active rheumatoid arthritis (RA), polyarticular juvenile RA, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. Randomized clinical trials have shown that it improves the signs and symptoms of early and long-standing RA and other inflammatory arthritides, prevents radiographic progression and improves the patients health-related quality of life. It is more effective when combined with methotrexate than alone. It is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by clinical trials, long-term observational studies and postmarketing surveillance over 12 years use in clinical practice. It slightly increases the risk of serious infections. The incidence of malignancies during clinical trials and postmarketing surveillance is no different from that expected in the general population, except for the greater frequency of lymphoma. However, this is closely related to current RA activity and therefore suggests that it is not directly related to the drug. This article considers the published data in terms of clinical practice and changes in the progression of RA.
KW - adverse events
KW - clinical efficacy
KW - etanercept
KW - pharmacokinetics
KW - safety
KW - trials
UR - http://www.scopus.com/inward/record.url?scp=84858409214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858409214&partnerID=8YFLogxK
U2 - 10.1586/eci.12.6
DO - 10.1586/eci.12.6
M3 - Article
C2 - 22390484
AN - SCOPUS:84858409214
VL - 8
SP - 213
EP - 222
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
SN - 1744-666X
IS - 3
ER -